Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19
Status:
Not yet recruiting
Trial end date:
2024-01-31
Target enrollment:
Participant gender:
Summary
A randomized, double-Blind, placebo-controlled trial aimed to investigate the safety and
efficacy of sivelestat on treating adult patients with COVID-19-related acute respiratory
distress syndrome (ARDS)